1-3 of 3
Zixun Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6928.
https://doi.org/10.1182/blood-2023-181351
Published: 2023
Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao
Journal: Blood
Blood (2019) 134 (Supplement_1): 1556.
https://doi.org/10.1182/blood-2019-122369
Published: 2019
Journal Articles

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Zixun Yan, Wen Wang, MD, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Wei-li Zhao
Journal: Blood
Blood (2018) 132 (Supplement 1): 4187.
https://doi.org/10.1182/blood-2018-99-115769
Published: 2018